cyc 682 has been researched along with on 01910 in 1 studies
Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (on 01910) | Trials (on 01910) | Recent Studies (post-2010) (on 01910) |
---|---|---|---|---|---|
30 | 5 | 18 | 80 | 13 | 69 |
Protein | Taxonomy | cyc 682 (IC50) | on 01910 (IC50) |
---|---|---|---|
Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | 0.009 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jabbour, E; Kadia, TM; Kantarjian, H | 1 |
1 review(s) available for cyc 682 and on 01910
Article | Year |
---|---|
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Drug Resistance; Drug Substitution; Enzyme Inhibitors; Glutathione; Glycine; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation; Sulfones; Treatment Failure | 2011 |